Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that following the receipt of approval from the United States Food and Drug Administration (USFDA) for our products registered under DUG (OTC), the Company has commenced execution of orders for the said products in the U.S. market.The USFDA approval was received on 16th May, 2025 and commercial execution of orders has commenced by execution of 3 FCL shipments till date and now with the receipt of new orders from the customer, Company targets to dispatch 4 to 5 shipments on monthly basis to the US customer. This development is expected to contribute positively to the Company''s revenues and presence in the regulated market.
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Filed with BSE · · 3 pages · English
Release
Veerhealth Care Limited on 6ix
Earlier from Veerhealth Care
- Veerhealth Care Limited Press Release Jul 09 2025
- Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Veerhealth Care Limited Press Release Jul 07 2025
- Announcement Under Regulation 30 (LODR) - Contract Manufacturing Agreement With Leading Marketplace Company
- Veerhealth Care Limited Press Release Jul 04 2025
Later from Veerhealth Care
- Veerhealth Care Limited Press Release Jul 23 2025
- Veerhealth Care Limited Press Release Jul 25 2025
- Updates
- Veerhealth Care Limited Press Release Jul 29 2025
- Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June, 2025.
Follow Veerhealth Care into a list and get an email when it puts out news.
Follow Veerhealth Care